| Revenue Growth | Royalty receipts grew 12% YTD; portfolio receipts grew 9% in Q3. |
|---|---|
| Mgmt Confidence | High; raised guidance for third consecutive quarter citing excellent business momentum. |
| Demand Visibility | Robust deal pipeline supported by $1 trillion expected biopharma R&D spend. |
| Margin Trends | Adjusted EBITDA margin 82% year-to-date; operating costs 5.6% of receipts. |
| Op. Leverage | Internalization of manager in 2025 delivering significant cash savings. |
| Vol vs Price | Growth driven by diversified portfolio performance and new royalty acquisitions. |
| Segment Growth | Tremfya, Erleada, Evrisdy, and Orserdu were key growth drivers. |
| New Clients | New R&D co-funding deals with J&J and Teva totaling $1 billion. |
| Capex & Debt | Deployed $1.6B YTD; $8.8B investment-grade debt; 2.5x net leverage. |
| Regulatory | Six FDA approvals and three filings in 2026; 90% development success. |
| Commentary | Focusing on being the premier capital allocator in life sciences innovation. |
| New Launches | FDA approvals for Voronigo (schizophrenia) and Augtyro (pancreatic cancer). |
Growth
Portfolio receipts grew 9% to $890 million; royalty receipts grew 12% year-to-date.
Outlook
Raised 2026 portfolio receipts guidance to $3.5B-$3.55B; targeting $4.7B top line by 2030.
Risks
Management provided limited specifics on Alpassaran economics following the Pelacarsin Phase 3 failure.
The company's earnings call, NASDAQ: RPRX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Royalty Pharma plc: key numbers
- Share price
- $68.53Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Royalty Pharma plc
All →Royalty Pharma Q3 2026 Results: Net Income $145M, Down 49.1% YoY
Royalty Pharma reported total income and other revenues of $1.99 billion for the first nine months of 2026, up from $1.76 billion in the prior year period. Despite the revenue growth, consolidated net income for the nine-month period decreased to $816.4 million from $967.3 million, primarily due to higher interest expenses and a $219.8 million impairment on financial royalty assets.
- Key figure
- Net income $145M · -49.1% YoY
Royalty Pharma Financial Results
Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.
- Term
- Q3 2026
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”
Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board
Royalty Pharma EVP, Research & Investments Marshall Urist Sells $236K of Stock
Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.10 a share, worth $236K in total on Oct 5, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $236K
- Shares
- 4,126
- Price
- $57.10
- Role
- EVP, Research & Investments
- Holding change
- -100.0%
- Trade date
- Oct 5, 2026
Royalty Pharma EVP, Research & Investments Marshall Urist Sells $239K of Stock
Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.88 a share, worth $239K in total on Sep 28, 2026. Shares held after the trade: 4,126 (-50.0%).
- Value
- $239K
- Shares
- 4,126
- Price
- $57.88
- Role
- EVP, Research & Investments
- Holding change
- -50.0%
- Trade date
- Sep 28, 2026
Royalty Pharma EVP & Chairman, Partnering Christopher Hite Sells $5.85M of Stock
Christopher Hite, EVP & Chairman, Partnering, sold 100,000 shares of Royalty Pharma plc at $58.51 to $58.93 a share (average $58.53) in 2 transactions, worth $5.85M in total on Sep 22, 2026. Shares held after the trade: 270,401 (-1.4%).
- Value
- $5.85M
- Shares
- 100,000
- Average price
- $58.53
- Role
- EVP & Chairman, Partnering
- Holding change
- -1.4%
- Trade date
- Sep 22, 2026